Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Recbio Technology Co., Ltd.
江蘇瑞科生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 02179)

PROPOSED APPOINTMENT OF A DIRECTOR APPOINTMENT OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE

PROPOSED APPOINTMENT OF A DIRECTOR

The board of directors (the "**Board**") of Jiangsu Recbio Technology Co., Ltd. (the "**Company**") is pleased to announce that, at the Board meeting convened on November 18, 2026, the Board nominated Ms. JIANG Chunyan (姜春燕) ("**Ms. JIANG**") as an executive director of the Company for a term commencing from the date of approval by the general meeting of the Company and ending upon the expiry of the term of office of the second session of the Board, and she is eligible for re-election upon expiry of her term.

The biographical details of Ms. JIANG are set out as follows:

Ms. JIANG Chunyan (姜春燕), aged 37, a member of the Communist Party of China, holds a bachelor's degree in pharmacy from Nanjing Medical University and is currently pursuing an MBA at Soochow University. She currently serves as the head of the Board Office of the Company. Ms. JIANG has 17 years of experience in the pharmaceutical manufacturing industry, mainly covering pharmaceutical production and operations, quality management, new product management, administrative coordination, human resources management, intelligent manufacturing upgrades and government project applications.

Ms. JIANG worked at Yangtze River Pharmaceutical (Group) Co., Ltd. (揚子江藥業集團有限公司) from November 2009 to August 2026, of which she held management positions for approximately 16 years from September 2010, successively serving as production team leader, assistant workshop director (in charge of work), deputy workshop director (in charge of work), factory office manager and deputy head (in charge of departmental work), and also worked at the human resources department on a rotational basis for half a year. During her tenure, Ms. JIANG was fully responsible for the management of several core workshops, including the anti-tumor solid dosage form workshop and the solid dosage form workshop, managing over 400 personnel; she was responsible for the coordination of production planning, quality control, personnel management, small trials and pilot tests of new products, process validation, obtaining approval to commence production and cross-departmental coordination. From April 2023, she was in charge of the factory office, coordinating the business of various departments in accordance with the instructions of the factory director, including the advancement of management optimisation, process optimisation, corporate culture development, government project applications and patent applications. During her tenure, she also participated in CMO/CDMO business and international sales business.

Ms. JIANG holds the professional title of intermediate engineer, the qualification of human resources manager, the qualification of psychological counsellor and the occupational qualification of pharmaceutical preparation worker (technician). Ms. JIANG was awarded "Taizhou Civilised Employee (泰州市文明職工)" in 2014, and was recognised by the Taizhou Talent Office as "Sixth Phase of 311 High-level Talent Cultivation Special Programme – Third-tier Talent (第六期311高層次人才培養專項—— 第三層次人才)" in February 2024. During her tenure, Ms. JIANG was repeatedly honoured with titles such as "Outstanding Communist Party Member", "Model Worker", "Pacesetter" and "Outstanding Management Cadre". In addition, Ms. JIANG successfully completed a one-and-a-half-year training programme for board secretaries in the Yangtze River Academy system and graduated as an outstanding participant, and participated as a co-author in two SCI academic papers.

The Company will enter into a director's service contract with Ms. JIANG upon approval at the general meeting. Ms. JIANG will receive remuneration in accordance with her positions held in the Company, and her allowance as an executive director of HK$320,000 per annum (before tax) is included in the total remuneration for her positions held in the Company.

Save as disclosed above, Ms. JIANG has confirmed that, as at the date of this announcement: (1) she has not held directorships in other listed companies in the past three years, nor does she have any other major appointments and professional qualifications; (2) she does not hold any position in the Company or the Company's subsidiaries; (3) she has no relationship with any director, senior management, substantial shareholder or controlling shareholder of the Company or any subsidiary of the Company; and (4) she does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of other information on the proposed appointment of Ms. JIANG which shall be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (the "**Listing Rules**"), and there are no other matters relating to the proposed appointment of Ms. JIANG that need to be brought to the attention of the shareholders of the Company.

A circular containing, among other matters, the proposed appointment, together with the notice of the general meeting, will be provided to the shareholders of the Company in due course.

APPOINTMENT OF JOINT COMPANY SECRETARY

Reference is made to the announcement of the Company dated August 25, 2026 in relation to, among other things, the resignation of a joint company secretary of the Company (the "**Joint Company Secretary**"). The Board is pleased to announce that the Company has appointed Ms. JIANG as a Joint Company Secretary with effect from November 18, 2026.

Ms. SUEN Ka Yan (孫嘉恩) ("**Ms. SUEN**"), the other company secretary of the Company who possesses the professional qualifications required under Rule 3.28 of the Listing Rules, will continue to serve as the other Joint Company Secretary of the Company. Ms. SUEN, in her capacity as a Joint Company Secretary, will work closely with Ms. JIANG and assist Ms. JIANG in discharging her duties as a Joint Company Secretary and in gaining the relevant experience as required under Rule 3.28 of the Listing Rules.

The biographical details of Ms. JIANG are set out above.

The biographical details of Ms. SUEN are set out as follows:

Ms. SUEN Ka Yan (孫嘉恩) is a manager of SWCS Corporate Services Group (Hong Kong) Limited (方圓企業服務集團(香港)有限公司). She has over ten years of professional experience in the company secretarial field and has been providing company secretarial services to listed and private companies incorporated in Hong Kong and overseas. Ms. SUEN is an associate of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. She obtained a bachelor's degree in law from the University of Lancashire in the United Kingdom.

As Ms. JIANG currently does not possess the qualifications of a company secretary as required under Rules 3.28 and 8.17 of the Listing Rules, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver (the "**Waiver**") in respect of the appointment of Ms. JIANG as the Joint Company Secretary, valid for a period of three years from November 18, 2026 (the "**Waiver Period**"), on the conditions that: (i) Ms. JIANG will be assisted by Ms. SUEN during the Waiver Period; and (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company. The Company shall announce the reasons for, details and conditions of the Waiver, as well as the qualifications and experience of Ms. JIANG and Ms. SUEN. The Stock Exchange may withdraw or change the Waiver if the Company's situation changes.

Before the end of the Waiver Period, the Company must demonstrate and seek confirmation from the Stock Exchange that Ms. JIANG, having had the benefit of the assistance from Ms. SUEN during the Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

CHANGE OF AUTHORISED REPRESENTATIVE

The Board hereby announces that, with effect from November 18, 2026, Dr. WANG Ruwei (王如偉) will cease to act as an authorised representative of the Company as required under Rule 3.05 of the Listing Rules (the "**Authorised Representative**"). Ms. JIANG, a Joint Company Secretary of the Company, has been appointed as an Authorised Representative with effect from November 18, 2026.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Mr. XU Haoyu
Chairman

Jiangsu Province, the PRC, November 18, 2026

As at the date of this announcement, the Board comprises Mr. XU Haoyu as the chairman of the Board and a non-executive director, Dr. LIU Yong and Ms. WANG Jing as executive directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive directors.